We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SW:NYSESmurfit WestRock plc Analysis

Data as of 2026-09-04 - not real-time

$45.85

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Smurfit Westrock Plc trades at $45.85, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. Across the trailing 30 sessions it lost 5.6%. Momentum indicators put RSI at 43.6 (neutral) with MACD reading bearish. Watch $44.41 as support and $50.52 as the nearer resistance level.
On valuation the read is fair — an earnings multiple of 48.8, absent a reliable peer benchmark. Analyst price targets sit 23.7% above the current price.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 37.7%, a beta of 1.48 and a maximum drawdown of 31.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
This one splits by horizon — buy in the near term, hold further out, at 4/10 long-term conviction.

Top Market Events

Smurfit Westrock plc NYSE:SW plans to release its financial results for the second quarter ended June 30, 2026 on...DUBLIN, July 15, 2026--Smurfit Westrock plc NYSE:SW plans to release its financial results for the second quarter ended...Smurfit Westrock SW doesn't possess the right combination of the two key ingredients for a likely earnings beat in its...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 42.42
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 42.42
  • Analyst targets imply +23.7% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Analyst targets imply +23.7% versus the current price
  • P/E ratio of 48.8
  • Price-to-book of 1.33

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin1.59%
P/E Ratio48.8
ROE2.71%
ROA2.62%
Debt/Equity78.43
P/B Ratio1.3
Op. Cash Flow$3.3B
Free Cash Flow$1.2B

Technical Analysis

TrendBullish
RSI43.6
Support$44.41
Resistance$50.52
MA 20$48.03
MA 50$46.71
MA 200$42.42
MACDBearish
VolumeStable
Fear & Greed Index96.05

Valuation

Fair Value$4.96
Target Price$56.72
Upside/Downside23.71%
GradeFair
TypeBlend

Risk Assessment

Beta1.48
Volatility37.74%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.